<DOC>
	<DOCNO>NCT01219751</DOCNO>
	<brief_summary>To evaluate efficacy safety sunitinib non-clear cell type renal cell carcinoma exception pure sarcomatoid carcinoma collect duct carcinoma</brief_summary>
	<brief_title>Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma</brief_title>
	<detailed_description>There standard treatment non-clear cell renal cell carcinoma . Retrospective study show sunitinib sorafenib might active non-clear cell renal cell carcinoma , especially papillary type chromophobe type . This study evaluate efficacy safety sunitinib group patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Histologically cytologically confirmation renal cell carcinoma without clear cell histologic component , e.g. , papillary type , chromophobe type , collect duct type 2 . Patients stage IV recurrent disease amenable surgery , radiotherapy , combine modality therapy curative intent . 3 . Measurable disease accord RECIST criterion 4 . ECOG performance status 1 well 5 . Age 18 year old 6 . Adequate cardiac function 7 . Adequate bone marrow , hepatic , renal function 8 . Life expectancy â‰¥ 3 month 9 . Singed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment 1 . Clear cell type renal cell carcinoma sarcomatoid carcinoma without clue primary type 2 . Diagnosis serious secondary malignancy within last 2 year , except adequately treat basal cell squamous cell carcinoma skin , situ carcinoma cervix uteri 3 . Hypertension control medication ( blood pressure &gt; 150/90 mmHg despite optimal medical therapy ) 4 . Treatment anticonvulsant agent treatment therapeutic dos coumadin currently within 2 week prior first day sunitinib administration . Low dose coumadin DVT prophylaxis permit ( 2 mg/day ) . 5 . Pregnancy breast feed . 6 . Other severe acute chronic medical psychiatric condition 7 . Prior treatment sunitinib , sorafenib , bevacizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>